Roberto García-Swinburn

Roberto García-Swinburn

Auto-generated profile, based on publicly available information

Roberto García-Swinburn

Instituto de Biomedicina de Sevilla (IBiS) Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla Sevilla Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
JVJavier Villadiego
Javier Villadiego
JGJuan García-Arriaza
Juan García-Arriaza
RRReposo Ramírez-Lorca
Reposo Ramírez-Lorca
RGRoberto García-Swinburn
Roberto García-Swinburn
DCDaniel Cabello-Rivera
Daniel Cabello-Rivera
JTJuan José Toledo-Aral
Juan José Toledo-Aral

22 June 2018 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
JVJavier Villadiego
Javier Villadiego
SRSonia Romo‐Madero
Sonia Romo‐Madero
RGRoberto García‐Swinburn
Roberto García‐Swinburn
NSNela Suárez‐Luna
Nela Suárez‐Luna
ABAlfonso Bermejo‐Navas
Alfonso Bermejo‐Navas
JTJuan José Toledo-Aral
Juan José Toledo-Aral

4 February 2022 in Research Square
Verified
Preprint
Open access
PDF file
JVJavier Villadiego
Javier Villadiego
JGJuan García-Arriaza
Juan García-Arriaza
RRReposo Ramírez-Lorca
Reposo Ramírez-Lorca
DCDaniel Cabello-Rivera
Daniel Cabello-Rivera
MÁMaría I. Álvarez-Vergara
María I. Álvarez-Vergara
JTJuan Toledo-Aral
Juan Toledo-Aral
The protective efficacy of vaccines against SARS-CoV-2 infection in the brain is yet unclear. Here, in the susceptible transgenic K18-hACE2 mouse model of severe COVID-19 disease, we report a detailed spatiotemporal description of the SARS-CoV-2 infection and replication in different areas of the brain. Remarkably, SARS-CoV-2 brain replication occurs primarily in neurons, producing important neuropathological alterations such as neuronal loss, incipient signs of neuroinflammation, and vascular damage in SARS-CoV-2 infected mice. Notably, one or two doses of a modified vaccinia virus Ankara (MVA) vector expressing the SARS-CoV-2 spike (S) protein (MVA-CoV2-S) conferred full protection against SARS-CoV-2 cerebral infection, preventing virus replication in all areas of the brain and its associated damage. This protection was maintained even after SARS-CoV-2 reinfection. To our knowledge, this is the first study of a COVID-19 vaccine candidate showing 100% efficacy against SARS-CoV-2 brain infection and damage, reinforcing the use of MVA-CoV2-S as a promising vaccine candidate against SARS-CoV-2/COVID-19, worth to move forward into clinical trials.

9 September 2026 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
RGRoberto García‐Swinburn
Roberto García‐Swinburn
LMLaura Morón‐Márquez
Laura Morón‐Márquez
CCCarmen Conde‐Naranjo
Carmen Conde‐Naranjo
EGErnesto García‐Roldán
Ernesto García‐Roldán
IEISABEL ESPADAS
ISABEL ESPADAS
JTJuan José Toledo-Aral
Juan José Toledo-Aral
LRRK2 G2019S mutation is the most common genetic cause of Parkinson's disease (PD) producing clinical manifestations similar to sporadic PD patients, hinting at the relevance of this mutation in the pathophysiological mechanisms of the disease. However, its role potentiating nigrostriatal neurodegeneration, particularly in response to mitochondrial dysfunction, remains unclear. Here, using histological, neurochemical and behavioral analyzes, we provide a complete characterization of a mouse model expressing the human LRRK2 G2019S mutation (hLRRK2*G2019S mice), in the context of aging and toxin‐induced parkinsonism. hLRRK2*G2019S young adult mice showed significant microglial activation and deficits in motor coordination, whereas aged transgenic displayed a hyperactive phenotype, despite the absence of evidence for nigrostriatal neurodegeneration in either young adult or aged animals. Furthermore, we assessed the vulnerability of LRRK2*G2019S transgenic mice to the chronic exposure to the mitochondrial complex I inhibitor 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Notably, no exacerbation of nigrostriatal neurodegeneration was observed in hLRRK2*G2019S mice, suggesting that this mutation does not increase sensitivity to mitochondrial stress. However, hLRRK2*G2019S MPTP‐treated mice present alterations, relative to WT counterparts, in the glial response induced by the neurotoxic treatment. These findings suggest that the G2019S mutation modulates the neuroimmune response but does not exacerbate nigrostriatal neurodegeneration in response to mitochondrial dysfunction. This highlights the mutation's complex role in PD pathophysiology. image

22 June 2025 in bioRxiv
Verified
Preprint
Open access
RGRoberto Garcia-Swinburn
Roberto Garcia-Swinburn
GLGuochang Lyu
Guochang Lyu
JKJudith C. Kreutzmann
Judith C. Kreutzmann
AXAnqi Xiong
Anqi Xiong
RKRika Kojima
Rika Kojima
EAErnest Arenas
Ernest Arenas
Parkinson’s disease (PD) is characterized by the progressive loss of midbrain dopaminergic (mDA) neurons, leading to severe debilitating motor impairment. Recent single-cell analyses have revealed that specific mDA subpopulations, such as SOX6⁺ AGTR1⁺ neurons, are most vulnerable to degeneration. Current human pluripotent stem cell differentiation protocols fail to selectively generate these subtypes. Here, we describe a multiomic-guided strategy that enriches SOX6 + mDA neurons by combining enhancing Sonic Hedgehog agonism with prolonged Wnt activation. This approach accelerates floor plate specification, increases expression of mDA developmental markers, and substantially increases the yield of SOX6⁺ mature mDA neurons compared to prior attempts. Following intrastriatal transplantation into hemiparkinsonian mice, these cells restored motor function in approximately 4 months and generated grafts containing SOX6⁺ A9-like neurons. Our work thus establishes a reproducible differentiation platform for generating the PD-susceptible mDA subtype, providing a foundation for precision disease modelling and subtype-targeted cell replacement therapies.